In this study, we investigated the immunoreactivity of the Technicon Immuno 1 PSA assay, a monoclonal-polyclonal sandwich immunoassay, with free and ACT-complexed PSA. Assay calibrators prepared with free PSA (standard Immuno 1 calibrators) and calibrators consisting of 90% ACT-complexed and 10% free PSA (90:10 calibrators) yielded virtually identical PSA recoveries at all concentrations tested. Concentrations of total PSA at approximately 4 and 10 ng/mL, prepared in varying ratios of free PSA to PSA-ACT complex, recovered from 92-104% at 4 ng/mL and from 98-102% at 10 ng/mL. Additionally, an excellent correlation of serum total PSA values from a panel of 40 prostatic cancer patient samples was obtained using calibration curves generated with the standard Immuno 1 calibrators or the 90:10 calibrators. These results demonstrate that the Technicon Immuno 1 PSA assay measures free and ACT-complexed PSA on an equal molar basis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/(SICI)1098-2825(1996)10:3<155::AID-JCLA8>3.0.CO;2-A | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps.
BMJ Oncol
April 2023
Department of Urology, Cancer Institute, Erasmus University Rotterdam, Rotterdam, Zuid-Holland, Netherlands.
Long-term screening with serum prostate-specific antigen (PSA) and systematic prostate biopsies can reduce prostate cancer mortality but leads to unacceptable overdiagnosis. Over the past decade, diagnostic methods have improved and the indolent nature of low-grade prostate cancer has been established. These advances now enable more selective detection of potentially lethal prostate cancer.
View Article and Find Full Text PDFPrevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study.
BMJ Oncol
August 2023
Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Objective: In men with a raised prostate-specific antigen (PSA), MRI increases the detection of clinically significant cancer and reduces overdiagnosis, with fewer biopsies. MRI as a screening tool has not been assessed independently of PSA in a formal screening study. We report a systematic community-based assessment of the prevalence of prostate MRI lesions in an age-selected population.
View Article and Find Full Text PDFBaseline Ultrasound Assessment Improves the Response to Apremilast in Patients with Psoriatic Arthritis: Results from a Multicentre Study.
Mediterr J Rheumatol
December 2024
Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy.
Background: Psoriatic arthritis (PsA) phenotypes show different responses to the many available drugs. For a tailored medicine, it is important to choose the most effective treatment according to patients' characteristics. Apremilast is recommended in PsA with moderate activity.
View Article and Find Full Text PDFAssociations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old men.
BMJ Oncol
September 2024
Department of Clinical Sciences, Urology, University of Gothenburg Sahlgrenska Academy, Goteborg, Sweden.
Objective: Population-based, organised prostate cancer testing (OPT) programmes were started in Sweden in 2020. The influence of socioeconomic factors on prostate cancer testing in this setting is not known. We examined associations between socioeconomic factors and (1) participation in OPT and (2) unorganised prostate-specific antigen (PSA) testing.
View Article and Find Full Text PDFLabel-free electrochemical immunoassay for ultra-sensitive detection of PSA utilizing gold nanoparticles/polyhedral hollow CoCu bimetallic sulfide nanostructure as a dual signal amplification platform.
Int J Biol Macromol
January 2025
Department of Analytical Chemistry, Faculty of Chemistry, Razi University, Kermanshah, Iran.
This study introduces the development of a highly sensitive label-free electrochemical immunosensor specifically designed to detect prostate-specific antigen (PSA). A glassy carbon electrode (GCE) coated with Au nanoparticles/polyhedral hollow CoCu bimetallic sulfide (CuCoS) was employed as a sensing interface for the fixation of the monoclonal anti-PSA antibody. The nanoarchitectures enhanced the capacity for loading prostate-specific antibodies (Ab) and effectually boosted electrical conductivity leading to enhance the electrochemical signal and greater sensitivity for the detection of PSA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!